Drug Profile

PMG 1015

Alternative Names: PMG-1015

Latest Information Update: 14 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Pulmongene
Class Antifibrotics; Monoclonal antibodies
Mechanism of Action MDK protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Idiopathic pulmonary fibrosis

Most Recent Events

17 May 2025 PMG 1015 is still in phase I trials for Idiopathic pulmonary fibrosis (IPF) (In volunteers) in Australia.
17 May 2025 Adverse events and pharmacokinetics pooled analysis data from a two phase Ia trial in healthy volunteers presented 121st International Conference of the American Thoracic Society (ATS 2025)
07 Feb 2025 Pulmongene completes a phase Ib trial in Idiopathic pulmonary fibrosis in China (IV) (NCT05895565)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com